The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 10, 2014, Pages 1377-1387

  Caliph, Suzanne M ^a   Faassen, Fried W ^b   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

^b NV ORGANON   (Netherlands)

Author keywords

brain deposition; drug absorption; lipid based formulation; lymphatic transport; poorly water soluble drugs

Indexed keywords

CAMPESTEROL; CENTRAL NERVOUS SYSTEM AGENTS; CHOLESTEROL; LIPOPROTEIN; LONG CHAIN FATTY ACID; ORG 49209; SITOSTEROL; UNCLASSIFIED DRUG; N METHYLASPARTIC ACID; NORSTEROID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TRANSPORT; EMULSION; INTESTINAL LYMPHATIC TRANSPORT; INTESTINE ABSORPTION; LIPID ABSORPTION; LIPID SOLUBILITY; LIPOPHILICITY; MALE; NONHUMAN; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; BRAIN; CHEMICAL STRUCTURE; INTESTINE; LYMPH; LYMPHATIC SYSTEM; METABOLISM; ORAL DRUG ADMINISTRATION; SCHIZOPHRENIA; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; CHOLESTEROL; INTESTINAL ABSORPTION; INTESTINES; LIPOPROTEINS; LYMPH; LYMPHATIC SYSTEM; MALE; MOLECULAR STRUCTURE; N-METHYLASPARTATE; NORSTEROIDS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA;

EID: 84923066917     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12268     Document Type: Article

References (64)

1. Autry AE, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91-95.
2. Kristiansen LV, et al. NMDA receptors and schizophrenia. Curr Opin Pharmacol 2007; 1: 48-55.
3. Li ST, Ju JG,. Functional roles of synaptic and extrasynaptic NMDA receptors in physiological and pathological neuronal activities. Curr Drug Targets 2012; 2: 207-221.
4. Schrattenholz A, Soskic V,. NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling. Curr Top Med Chem 2006; 7: 663-686.
5. Zhou Q, Sheng M,. NMDA receptors in nervous system diseases. Neuropharmacology 2013; 74: 69-75.
6. Lipinski CA, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
7. Rabinow BE,. Nanosuspensions in drug delivery. Nat Rev Drug Discov 2004; 3: 785-796.
8. Morishita M, Peppas NA,. Advances in oral drug delivery: improved bioavailability of poorly absorbed drugs by tissue and cellular optimization. Preface. Adv Drug Deliv Rev 2012; 6: 479.
9. Williams HD, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 2013; 1: 315-499.
10. Hauss DJ, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci 1998; 2: 164-169.
11. Khoo SM, et al. A conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. J Pharm Sci 2001; 10: 1599-1607.
12. Trevaskis NL, et al. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 2008; 6: 702-716.
13. Caliph SM, et al. Oral bioavailability assessment and intestinal lymphatic transport of Org 45697 and Org 46035, two highly lipophilic novel immunomodulator analogues. Curr Drug Deliv 2009; 4: 359-366.
14. Trevaskis NL, et al. The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles. Pharm Res 2010; 9: 1949-1964.
15. Trevaskis NL, et al. The role of the intestinal lymphatics in the absorption of two highly lipophilic cholesterol ester transfer protein inhibitors (CP524,515 and CP532,623). Pharm Res 2010; 5: 878-893.
16. Trevaskis NL, et al. Intestinal lymphatic transport enhances the post-prandial oral bioavailability of a novel cannabinoid receptor agonist via avoidance of first-pass metabolism. Pharm Res 2009; 26: 1486-1495.
17. Charman WN, Stella VJ,. Estimating the maximal potential for intestinal lymphatic transprot of lipophilic drug molecules. Int J Pharm 1986; 34: 175-178.
18. Clark SB, Tercyak AM,. Reduced cholesterol transmucosal transport in rats with inhibited mucosal acyl CoA: cholesterol acyltransferase and normal pancreatic function. J Lipid Res 2012; 53: 95-104.
19. Faisal W, et al. Bioavailability of lycopene in the rat: the role of intestinal lymphatic transport. J Pharm Pharmacol 2010; 3: 323-331.
20. Holm R, et al. Examination of oral absorption and lymphatic transport of halofantrine in a triple-cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. Eur J Pharm Sci 2003; 1: 91-97.
21. O'Driscoll CM,. Lipid-based formulations for intestinal lymphatic delivery. Eur J Pharm Sci 2002; 5: 405-415.
22. Porter CJ, et al. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 3: 231-248.
23. Karpf DM, et al. Influence of the type of surfactant and the degree of dispersion on the lymphatic transport of halofantrine in conscious rats. Pharm Res 2004; 8: 1413-1418.
24. Porter CJ, et al. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: effect of lipid vehicle dispersion. J Pharm Sci 1996; 4: 351-356.
25. Caliph SM, et al. Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies. J Pharm Sci 2012; 9: 3540-3546.
26. Gershkovich P, Hoffman A,. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci 2007; 1: 24-32.
27. Humberstone AJ, et al. Post-prandial hypertriglycaeridaemia affects the pharmacokinetics of halofantrine after intravenous administration to beagle dogs. Pharm Res 1995; 12: S356.
28. Gershkovich P, et al. Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211 220. Eur J Pharm Sci 2007; 5: 298-305.
29. Wasan KM, et al. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Discov 2008; 1: 84-99.
30. Caliph SM, et al. Effect of short-, medium-, and long-chain fatty acidbased vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats. J Pharm Sci 2000; 8: 1073-1084.
31. Holm R, et al. Comparison of the lymphatic transport of halofantrine administered in disperse systems containing three different unsaturated fatty acids. Pharm Res 2001; 9: 1299-1304.
32. Humberstone AJ, et al. A physicochemical basis for the effect of food on the oral bioavailability of halofantrine. J Pharm Sci 1996; 85: 525-529.
33. Sunesen VH, et al. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci 2005; 4: 297-303.
34. Caliph SM, et al. The impact of lymphatic transport on the systemic disposition of lipophilic drugs. J Pharm Sci 2013; 102: 2395-2408.
35. Singh B, et al. Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential. Drug Deliv 2011; 8: 599-612.
36. Boyd BJ, et al. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Mol Pharm 2006; 5: 614-627.
37. Edwards GA, et al. Animal models for the study of intestinal lymphatic drug transport. Adv Drug Deliv Rev 2001; 1-2: 45-60.
38. Hauss DJ, et al. Targeted lymphatic transport and modified systemic distribution of CI-976, a lipophilic lipid-regulator drug, via a formulation approach. Int J Pharm 1994; 2: 85-93.
39. Grove M, et al. Bioavailability of seocalcitol IV: evaluation of lymphatic transport in conscious rats. Pharm Res 2006; 11: 2681-2688.
40. Flynn GL, et al. Cholesterol solubility in organic solvents. J Pharm Sci 1979; 9: 1090-1097.
41. Charman WN,. Lipid vehicle and formulation effects on intestinal lymphatic drug transport. In:, Charman WN, Stella VJ, eds. Lymphatic Transport of Drugs. Boca Raton, FL: CRC press, 1992: 113-179.
42. Egwim PO, Kummerow FA,. Influence of dietary fat on the concentration of long-chain unsaturated fatty acid families in rat tissues. J Lipid Res 1972; 4: 500-510.
43. van Woudenbergh GJ, et al. Comparison of fatty acid proportions in serum cholesteryl esters among people with different glucose tolerance status: the CoDAM study. Nutr Metab Cardiovasc Dis 2012; 2: 133-140.
44. Green MH,. Chemical and isotopic measurement of cholesterol absorption in the rat. Atherosclerosis 1980; 3: 343-352.
45. Nguyen TM, et al. Cholesterol esterification by ACAT2 is essential for efficient intestinal cholesterol absorption: evidence from thoracic lymph duct cannulation. J Lipid Res 2012; 1: 95-104.
46. Field FJ, Mathur SN,. beta-sitosterol: esterification by intestinal acylcoenzyme A: cholesterol acyltransferase (ACAT) and its effect on cholesterol esterification. J Lipid Res 1983; 4: 409-417.
47. Holm R, et al. Comparison of total oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats. Eur J Pharm Sci 2001; 4: 331-337.
48. Porter CJ, Charman WN,. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 2001; 1-2: 61-80.
49. Sylven C, Borgstrom B,. Intestinal absorption and lymphatic transport of cholesterol in the rat: influence of the fatty acid chain length of the carrier triglyceride. J Lipid Res 1969; 4: 351-355.
50. Trevaskis NL, et al. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. Drug Metab Dispos 2006; 5: 729-733.
51. Trevaskis NL, et al. A mouse model to evaluate the impact of species, sex, and lipid load on lymphatic drug transport. Pharm Res 2013; 30: 3254-3270.
52. Tso P, et al. Factors regulating the formation of chylomicrons and very-low-density lipoproteins by the rat small intestine. Biochim Biophys Acta 1987; 3: 304-313.
53. Galia E, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 5: 698-705.
54. Porter CJ, Charman WN,. In vitro assessment of oral lipid based formu lations. Adv Drug Deliv Rev 2001; 50: S127-S147.
55. Soderlind E, et al. Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. Mol Pharm 2010; 5: 1498-1507.
56. Sylven C, Borgstrom B,. Absorption and lymphatic transport of cholesterol and sitosterol in the rat. J Lipid Res 1969; 2: 179-182.
57. Hui DY, et al. Development and physiological regulation of intestinal lipid absorption. III. Intestinal transporters and cholesterol absorption. Am J Physiol Gastrointest Liver Physiol 2008; 4: G839-G843.
58. Igel M, et al. Comparison of the intestinal uptake of cholesterol, plant sterols, and stanols in mice. J Lipid Res 2003; 3: 533-538.
59. Lammert F, Wang DQ,. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology 2005; 2: 718-734.
60. Schmitz G, et al. Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res 2001; 10: 1513-1520.
61. Sudhop T, et al. Comparison of the hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion. Gut 2002; 6: 860-863.
62. Tachibana S, et al. Cholesterol and plant sterol efflux from cultured intestinal epithelial cells is mediated by ATP-binding cassette transporters. Biosci Biotechnol Biochem 2007; 8: 1886-1895.
63. Wang DQ,. Regulation of intestinal cholesterol absorption. Annu Rev Physiol 2007; 69: 221-248.
64. Lukas G, et al. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther 1971; 178: 562-564.